395 related articles for article (PubMed ID: 19651290)
1. Mammalian target of rapamycin and autosomal dominant polycystic kidney disease.
Wüthrich RP; Serra AL
Transplant Proc; 2009; 41(6 Suppl):S18-20. PubMed ID: 19651290
[TBL] [Abstract][Full Text] [Related]
2. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
[TBL] [Abstract][Full Text] [Related]
5. Laparoscopic removal of renal cysts in patients with ADPKD as an alternative method of treatment and patient preparation for kidney transplantation: preliminary results.
Sulikowski T; Kamiński M; Rózański J; Zietek Z; Domański L; Majewski W; Sieńko J; Romanowski M; Mizerski A; Myślak M; Tejchman K; Pabisiak K; Nowacki M; Ostrowski M; Ciechanowski K
Transplant Proc; 2006; 38(1):23-7. PubMed ID: 16504654
[TBL] [Abstract][Full Text] [Related]
6. Experience with autosomal dominant polycystic kidney disease in patients before and after renal transplantation: a 7-year observation.
Sulikowski T; Tejchman K; Zietek Z; Rózański J; Domański L; Kamiński M; Sieńko J; Romanowski M; Nowacki M; Pabisiak K; Kaczmarczyk M; Ciechanowski K; Ciechanowicz A; Ostrowski M
Transplant Proc; 2009; 41(1):177-80. PubMed ID: 19249508
[TBL] [Abstract][Full Text] [Related]
7. [Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option].
Serra AL; Wüthrich RP
Praxis (Bern 1994); 2009 Dec; 98(25):1511-6. PubMed ID: 20013687
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous renal transplantation and native nephrectomy in patients with autosomal-dominant polycystic kidney disease.
Nunes P; Mota A; Alves R; Figueiredo A; Parada B; Macário F; Rolo F
Transplant Proc; 2007 Oct; 39(8):2483-5. PubMed ID: 17954154
[TBL] [Abstract][Full Text] [Related]
9. Everolimus in patients with autosomal dominant polycystic kidney disease.
Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
[TBL] [Abstract][Full Text] [Related]
10. Concomitant nephrectomy of massively enlarged kidneys and renal transplantation in autosomal dominant polycystic kidney disease.
Tabibi A; Simforoosh N; Abadpour P; Gholamrezaie HR; Nafar M
Transplant Proc; 2005 Sep; 37(7):2939-40. PubMed ID: 16213267
[TBL] [Abstract][Full Text] [Related]
11. Autosomal dominant polycystic kidney disease: clinical and genetic aspects.
Sessa A; Ghiggeri GM; Turco AE
J Nephrol; 1997; 10(6):295-310. PubMed ID: 9442442
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
[TBL] [Abstract][Full Text] [Related]
13. Management of ESRD in patients with autosomal dominant polycystic kidney disease.
Alam A; Perrone RD
Adv Chronic Kidney Dis; 2010 Mar; 17(2):164-72. PubMed ID: 20219619
[TBL] [Abstract][Full Text] [Related]
14. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.
Serra AL; Kistler AD; Poster D; Struker M; Wüthrich RP; Weishaupt D; Tschirch F
BMC Nephrol; 2007 Sep; 8():13. PubMed ID: 17868472
[TBL] [Abstract][Full Text] [Related]
15. Autosomal dominant polycystic kidney disease: time for a change?
Chapman AB
J Am Soc Nephrol; 2007 May; 18(5):1399-407. PubMed ID: 17429048
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic interventions for autosomal dominant polycystic kidney disease.
Edelstein CL
Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
[TBL] [Abstract][Full Text] [Related]
17. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.
Leonhard WN; van der Wal A; Novalic Z; Kunnen SJ; Gansevoort RT; Breuning MH; de Heer E; Peters DJ
Am J Physiol Renal Physiol; 2011 May; 300(5):F1193-202. PubMed ID: 21345977
[TBL] [Abstract][Full Text] [Related]
18. Autosomal dominant polycystic kidney disease (ADPKD, MIM 173900, PKD1 and PKD2 genes, protein products known as polycystin-1 and polycystin-2).
Boucher C; Sandford R
Eur J Hum Genet; 2004 May; 12(5):347-54. PubMed ID: 14872199
[TBL] [Abstract][Full Text] [Related]
19. Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis.
Pereira TV; Nunes AC; Rudnicki M; Magistroni R; Albertazzi A; Pereira AC; Krieger JE
Nephrol Dial Transplant; 2006 Nov; 21(11):3155-63. PubMed ID: 16935894
[TBL] [Abstract][Full Text] [Related]
20. Influence of VEGF polymorphism on progression of autosomal dominant polycystic kidney disease.
Reiterová J; Obeidová H; Lenícek M; Stekrová J; Merta M; Maixnerová D; Vítek L; Viklický O; Tesar V
Kidney Blood Press Res; 2008; 31(6):398-403. PubMed ID: 19060482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
